Industry Overview

Varicose veins treatment market was valued at $1.3 billion in 2025 and is projected to reach $2.5 billion by 2035, growing at a CAGR of 6.5% during the forecast Period (2026-2035). The growth is driven by the rising prevalence of venous diseases due to aging, obesity, and sedentary lifestyles, alongside increasing demand for minimally invasive procedures (like EVLT & RFA) and better awareness. Its key factors include technological advancements, patient preference for outpatient treatments, expanding insurance, and rising healthcare expenditure, with opportunities in emerging markets like the Asia-Pacific region, though high costs and a lack of skilled professionals pose challenges.

Market Dynamics

Rising Prevalence of Varicose Veins and Aging Population

One of the most significant drivers fueling the expansion of the global varicose veins treatment market is the increasing incidence of venous disorders, particularly among the aging global population. As life expectancy rises worldwide, the prevalence of varicose veins which results from weakened vein walls and dysfunctional valves, increases as well. Elderly individuals, especially those over 50, are more prone to developing varicose veins due to decreased vascular elasticity and prolonged exposure to risk factors such as reduced mobility. Combined with broader lifestyle contributors like obesity and sedentary habits, the overall burden of venous insufficiency has grown, prompting greater demand for effective treatment options across both developed and emerging regions. This demographic shift is a foundational driver, expanding the patient pool and encouraging healthcare providers to offer a wider range of therapies.

Technological Advancements and Minimally Invasive Procedures

Technology innovation is transforming how varicose veins are treated, shifting preference from traditional surgical interventions to minimally invasive procedures that deliver quicker recovery, fewer complications, and improved patient comfort. Procedures such as endovenous laser therapy (EVLT), radiofrequency ablation (RFA), ultrasound?guided sclerotherapy, and newer adhesive?based closure systems are gaining widespread clinical acceptance. These advanced treatment options are less traumatic, often outpatient?based, and tend to offer superior cosmetic and functional results compared with older surgical stripping techniques. The development and adoption of cutting?edge devices and imaging technologies not only make the procedures more effective but also expand treatment accessibility by enabling physicians to treat a broader range of vein conditions with precision and safety.

Growing Awareness, Cosmetic Demand, and Healthcare Accessibility

Another key driver is the rising patient awareness of both the health risks and aesthetic implications of varicose veins, combined with improved access to healthcare services. Public education campaigns and increased dissemination of information through digital media have helped patients recognize varicose veins as a treatable clinical issue rather than merely a cosmetic concern. As a result, more people are seeking treatment not just for discomfort but also for appearance?related outcomes. Furthermore, in many developed markets, favorable reimbursement policies and insurance coverage have made clinically indicated varicose vein interventions more affordable, encouraging higher procedural uptake. In emerging markets, expanding healthcare infrastructure, rising disposable incomes, and the growth of specialized vascular clinics continue to broaden access, drawing new patients into formal treatment pathways who might previously have delayed care due to cost or lack of services.

Market Segmentation

• Based on the type, the market is segmented into endovenous ablation, injection sclerotherapy, surgical ligation & stripping.
• Based on the end-user, the market is segmented into hospitals, ambulatory surgical centers, and specialty clinics.

Endovenous Ablation Segment to Grow at a Considerable Market Share

Endovenous ablation segment under the treatment type category, which represents the largest share of the market. This dominance is driven by the increasing preference for minimally invasive procedures over traditional surgical methods due to their higher efficacy, reduced recovery time, and lower complication rates. Among endovenous ablation techniques, endovenous laser therapy (EVLT) and radiofrequency ablation (RFA) have gained particular traction, offering precise vein closure with minimal patient discomfort. These procedures can often be performed on an outpatient basis, making them more convenient and cost-effective for patients compared to surgical ligation and stripping. The growing adoption of endovenous ablation is further supported by technological advancements, including improved catheter designs and imaging guidance, which enhance treatment outcomes and procedural safety. Consequently, this segment continues to dominate the global market, attracting both healthcare providers and patients seeking effective and minimally invasive varicose vein therapies.

Hospitals: A Key Segment in Market Growth

Hospitals remain the largest and most influential segment driving market growth. Hospitals account for the majority of treatment procedures due to their well-established infrastructure, availability of advanced surgical and minimally invasive devices, and presence of highly skilled vascular surgeons. They cater to both severe and moderate cases of varicose veins, offering comprehensive care from diagnosis to post-operative management. The high patient throughput in hospitals ensures consistent demand for ablation devices, sclerotherapy kits, and other treatment technologies, directly contributing to market revenue.

Furthermore, hospitals often serve as referral centers for specialty clinics and ambulatory surgical centers, consolidating their position as the primary revenue driver. In addition, hospitals in developed regions such as North America and Europe benefit from favorable insurance reimbursement policies, encouraging more patients to undergo procedures in these facilities rather than delaying treatment. Even in emerging markets, the expansion of private hospital chains and investment in vascular care programs is increasing procedural volumes. Overall, the hospital segment’s combination of advanced technology adoption, high procedural capacity, and strong patient trust makes it the key end-user segment propelling global varicose veins treatment market growth.

Regional Outlook

The global varicose veins treatment market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global Varicose Veins Treatment market, holding the largest share in terms of revenue and procedural volume. This leadership is primarily driven by the country’s advanced healthcare infrastructure, high patient awareness, and widespread adoption of minimally invasive treatment options such as endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and sclerotherapy. The US healthcare system’s strong emphasis on specialized vascular care, combined with the presence of numerous hospitals, ambulatory surgical centers, and specialty clinics, ensures that patients have easy access to state-of-the-art treatment options.

Additionally, favorable insurance coverage and reimbursement policies for varicose vein procedures encourage patients to opt for timely intervention, further boosting procedural numbers. Lifestyle factors such as increasing obesity rates and a growing aging population also contribute to a rising incidence of venous disorders, expanding the patient pool. The country is also home to leading medical device manufacturers, including Medtronic, Boston Scientific, and AngioDynamics, which actively invest in research and innovation, bringing newer, more effective treatment technologies to market. Combined, these factors make the United States not only the largest revenue-generating market but also a key trendsetter, influencing global clinical practices and adoption patterns in varicose veins treatment.

Market Players Outlook

The major companies operating in the global varicose veins treatment market include AngioDynamics, Inc., Boston Scientific Corp., Biolitec AG, Medtronic plc, Teleflex Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In July 2025, Medtronic launched the #KabTakKarogeIgnore campaign in India to raise awareness about varicose veins and promote early medical intervention. Varicose veins affect 15-20% of adults and have a higher prevalence than other cardiovascular conditions. Despite their serious implications, they are often mistakenly viewed as a cosmetic issue, leading individuals to seek alternative treatments without understanding the medical risks. The campaign emphasizes the importance of accurate information to help patients make informed decisions and advocates for early treatment to prevent worsening symptoms and complications.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global varicose veins treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.